Zynerba Pharma (ZYNE) Tops Q1 EPS by 7c

Zynerba Pharma (NASDAQ: ZYNE) reported Q1 EPS of ($0.49), $0.07 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.25 thousand versus the consensus estimate of $10 thousand.

Financial Outlook

Based on current operating plans, the Company expects that its existing cash and cash equivalents will fund its research and development programs and operations through 2017, which will include Phase 2 data readout for the five indications of ZYN002 and ZYN001.

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
• Evolution Petroleum closes $16M Midland Basin royalty acquisition